신경병증성 통증 치료제 시장 : 제품 유형별, 투여 경로별, 적응증별, 유통 채널별 시장 예측(2026-2032년)

The Neuropathic Pain Drug Market is projected to grow by USD 11.95 billion at a CAGR of 8.10% by 2032.

Neuropathic Pain Drug Market Introduction

Neuropathic pain drug development is moving from broad symptomatic management toward precision-oriented therapies that address diabetic neuropathy, postherpetic neuralgia, chemotherapy-induced peripheral neuropathy, spinal cord injury pain, trigeminal neuralgia, radiculopathy, and other nerve-injury syndromes. Epidemiological literature commonly estimates neuropathic pain prevalence at approximately 7% to 10% of the general population, making it a major clinical and economic burden for health systems, payers, and life sciences organizations.

Current treatment is anchored by guideline-supported options such as gabapentinoids, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, topical lidocaine, and high-concentration capsaicin, while opioids are increasingly restricted because of safety, dependency, and policy concerns. For pharmaceutical innovators, this creates a clear opportunity for differentiated neuropathic pain medications with improved tolerability, faster onset, disease-specific efficacy, lower discontinuation, and evidence suitable for value-based reimbursement.

Transformative Shifts in the Neuropathic Pain Landscape

The neuropathic pain drug landscape is being reshaped by the rising prevalence of diabetes, cancer survivorship, aging populations, and nerve injury associated with surgery, trauma, infections, and autoimmune disorders. The International Diabetes Federation reported 537 million adults living with diabetes in 2021, with projections rising to 643 million by 2030 and 783 million by 2045, supporting sustained clinical need for diabetic peripheral neuropathy therapies.

At the same time, clinical practice is moving away from one-size-fits-all analgesia. Regulators and payers increasingly expect robust patient-reported outcomes, functional improvement, comparative effectiveness, and safety evidence. Pipeline strategies are therefore prioritizing non-opioid mechanisms, sodium channel modulation, calcium channel modulation, neuroinflammation pathways, cannabinoid-related approaches where permitted, and combination regimens that can address heterogeneous neuropathic pain biology.

Cumulative Impact of Artificial Intelligence in Neuropathic Pain Drug Development

Artificial intelligence is cumulatively improving neuropathic pain drug discovery by accelerating target identification, compound screening, translational biomarker analysis, and clinical trial feasibility. AI-enabled natural language processing can analyze electronic health records to identify underdiagnosed neuropathic pain cohorts, while machine learning models can help stratify patients by symptom cluster, comorbidity, prior medication response, polypharmacy risk, and likelihood of treatment discontinuation.

The greatest near-term value is expected in trial design, pharmacovigilance, and real-world evidence generation rather than fully autonomous drug discovery. AI can support adaptive recruitment, detect safety signals earlier, and integrate wearable, claims, imaging, omics, and patient-reported data. For industry leaders, governance remains essential because pain outcomes are subjective, datasets can be biased, and regulatory acceptance requires transparency, validation, auditability, and reproducibility.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East & Africa

Asia-Pacific is one of the most dynamic demand centers because China, India, Japan, South Korea, and Australia combine large diabetes populations, aging demographics, expanding pain specialty care, and growing access to branded generics and innovative medicines. Japan and Australia have mature reimbursement systems and stronger clinical guideline adoption, while China and India offer substantial patient-volume potential but require localized pricing, evidence generation, physician education, and distribution strategies.

North America remains the most commercially advanced region, led by the United States and Canada, where established diagnosis pathways, specialist networks, payer scrutiny, and opioid-sparing policies favor evidence-backed non-opioid neuropathic pain drugs. Latin America is gaining relevance as Brazil and Mexico expand diabetes management and private healthcare access, although affordability and formulary inclusion remain central to uptake.

Europe benefits from strong clinical research infrastructure, centralized regulatory pathways, and widespread use of health technology assessment, but access varies by country-level reimbursement criteria and cost-effectiveness thresholds. The Middle East, particularly high-income Gulf health systems, is shaped by significant diabetes and obesity burdens, investment in specialty care, and tender-led procurement. Africa represents a longer-term access opportunity, where underdiagnosis, limited pain specialist availability, medicine affordability, and primary-care capacity influence the adoption of neuropathic pain therapies.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7 & NATO

ASEAN markets are gaining relevance as diabetes prevalence rises and access to neurology, endocrinology, and pain management services expands in urban centers. Entry strategies are strongest where organizations combine physician education, affordable formulations, pharmacovigilance readiness, and local distributor partnerships. The GCC presents a high-priority opportunity because diabetes and obesity burdens are significant, health systems are investing in specialty care, and branded medicines can gain traction when supported by clinical evidence, tender readiness, and compliant local registration strategies.

The European Union offers scale through harmonized regulatory science and established clinical guidance, but country-specific reimbursement remains decisive for patient access. BRICS countries provide large patient pools, expanding clinical trial activity, and manufacturing advantages, particularly in China, India, and Brazil, yet pricing pressure and procurement requirements are intense. G7 markets remain innovation leaders with strong clinical trial capacity, advanced pharmacovigilance systems, and high evidentiary expectations. NATO-aligned markets overlap substantially with North America and Europe, where supply-chain resilience, secure health data infrastructure, medicine availability, and regulatory alignment are increasingly strategic priorities for neuropathic pain drug commercialization.

Key Country Insights Across Major Neuropathic Pain Drug Markets

The United States is the anchor country for neuropathic pain drug commercialization because of its large diagnosed diabetes population, specialty prescribing base, established clinical trial ecosystem, and strong demand for opioid-sparing pain therapies, though payer controls, prior authorization, and step therapy can limit premium uptake. Canada offers stable reimbursement pathways and guideline-driven care, while Mexico provides growing access opportunities supported by expanding diabetes management, private healthcare demand, and broader use of branded generics. Brazil is a major Latin American opportunity due to its large chronic disease burden and mixed public-private healthcare system, where pricing, local evidence, and formulary access are decisive.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine high clinical standards with rigorous reimbursement assessment; Germany is particularly important for early benefit evaluation, while the United Kingdom emphasizes cost-effectiveness through national health technology appraisal. France, Italy, and Spain require strong clinical differentiation and budget-impact evidence, while Russia remains a complex access market shaped by localization, procurement dynamics, and regulatory requirements.

In Asia-Pacific, China and India offer the largest patient-volume opportunities because of diabetes burden, aging populations, and expanding healthcare access, but pricing, local data, and distribution depth are critical. Japan and South Korea provide high-value innovation markets with advanced clinical practice, aging demographics, and strong expectations for quality and safety evidence. Australia supports evidence-based adoption through structured reimbursement, specialist-led care, and clear payer scrutiny, making it important for therapies that can demonstrate clinically meaningful functional and quality-of-life benefits.

Actionable Recommendations for Neuropathic Pain Drug Leaders

Industry leaders should prioritize differentiated clinical profiles, not incremental claims. Development programs need to demonstrate meaningful pain reduction, sleep and function improvement, tolerability, reduced discontinuation, and applicability to defined neuropathic pain subtypes. Strong evidence in diabetic peripheral neuropathy and postherpetic neuralgia remains commercially important, while chemotherapy-induced peripheral neuropathy, trigeminal neuralgia, spinal cord injury pain, and other underserved conditions can support lifecycle expansion.

Commercial teams should align trial endpoints with payer expectations, build real-world evidence early, and prepare country-specific value dossiers. Organizations should also invest in AI-enabled patient identification, pharmacovigilance, adherence analytics, and digital outcome capture while maintaining rigorous data governance. Regional strategies should balance premium launches in G7 markets with affordable access models, branded generics, and partnerships in BRICS, ASEAN, Latin America, the Middle East, and Africa.

Research Methodology

This executive summary is based on secondary research from peer-reviewed neuropathic pain literature, clinical guidelines, regulatory labels, public health datasets, and recognized institutional sources, including international pain associations, diabetes federations, public health agencies, medicines regulators, and national health technology assessment bodies.

The methodology integrates epidemiology, approved treatment standards, pipeline direction, reimbursement dynamics, regional access conditions, artificial intelligence adoption, and technology-enabled evidence generation trends. Insights were triangulated across clinical, regulatory, commercial, and health-system evidence to avoid unsupported market claims and to provide practical intelligence for drug developers, investors, and commercialization teams.

Conclusion

The neuropathic pain drug market is positioned for sustained strategic importance as diabetes, aging, cancer survivorship, neurological disorders, and opioid-sparing treatment policies expand the need for safer and more effective therapies. While existing medicines remain essential, unmet needs persist in efficacy durability, tolerability, patient stratification, treatment adherence, and condition-specific evidence.

Organizations that combine differentiated non-opioid mechanisms, AI-supported development, robust real-world evidence, and localized market access strategies will be best placed to compete. Success will depend on proving value not only through pain score improvement but also through measurable gains in function, sleep, adherence, safety, quality of life, and health-system efficiency.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Neuropathic Pain Drug Market, by Product Type

• 7.1. Anticonvulsants
  • 7.1.1. Carbamazepine
  • 7.1.2. Gabapentin
  • 7.1.3. Lamotrigine
  • 7.1.4. Pregabalin
• 7.2. Antidepressants
  • 7.2.1. SNRIs
    • 7.2.1.1. Duloxetine
    • 7.2.1.2. Venlafaxine
  • 7.2.2. TCAs
    • 7.2.2.1. Amitriptyline
    • 7.2.2.2. Nortriptyline
• 7.3. Opioids
  • 7.3.1. Tapentadol
  • 7.3.2. Tramadol
• 7.4. Topical Agents
  • 7.4.1. Capsaicin
  • 7.4.2. Diclofenac Gel
  • 7.4.3. Lidocaine Patch

8. Neuropathic Pain Drug Market, by Route Of Administration

• 8.1. Intravenous
• 8.2. Oral
• 8.3. Topical
• 8.4. Transdermal

9. Neuropathic Pain Drug Market, by Indication

• 9.1. Chemotherapy-Induced Neuropathy
• 9.2. Diabetic Neuropathy
• 9.3. HIV-Associated Neuropathy
• 9.4. Post-Herpetic Neuralgia

10. Neuropathic Pain Drug Market, by Distribution Channel

• 10.1. Hospitals Pharmacy
• 10.2. Retail Pharmacies
• 10.3. Specialty Clinics

11. Neuropathic Pain Drug Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Neuropathic Pain Drug Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Neuropathic Pain Drug Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Concentration Analysis, 2025
  • 14.1.1. Concentration Ratio (CR)
  • 14.1.2. Herfindahl Hirschman Index (HHI)
• 14.2. Recent Developments & Impact Analysis, 2025
• 14.3. Product Portfolio Analysis, 2025
• 14.4. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. AcelRx Therapeutics, Inc.
• 15.2. Bausch Health Companies Inc.
• 15.3. Eli Lilly and Company
• 15.4. Endo International plc
• 15.5. Grunenthal GmbH
• 15.6. Hikma Pharmaceuticals PLC
• 15.7. Mylan N.V.
• 15.8. Novartis AG
• 15.9. Pfizer Inc.
• 15.10. Sanofi S.A.
• 15.11. Teva Pharmaceutical Industries Ltd.